RAPID COMMUNICATION

TP53 and XRCC1 polymorphisms and breast cancer prognosis: a case-case study

Marina Silva Rodrigues,1 Camila Almeida Machado,1 Dante Pagnoncelli,II Elizabeth Avvad,III Júlio César da Paixão,IV Claudia Vitória de Moura GalloI

1Universidade do Estado do Rio de Janeiro - Departamento de Genética, Rio de Janeiro/RJ, Brazil. II FIOCRUZ - Departamento de Patologia-IFF, Rio de Janeiro/RJ, Brazil. III FIOCRUZ - Departamento de Ginecologia-IFF, Rio de Janeiro/RJ, Brazil. IV FIOCRUZ - Biologia Molecular-IFF, Rio de Janeiro/RJ, Brazil.

Email: claudia.gallo@pq.cnpq.br
Tel.: 55 21 2334-0858

INTRODUCTION

Breast cancer is the most common cause of cancer death and the most common type of cancer in women.1 The State of Rio de Janeiro has the highest frequency of this disease in Brazil.2 Breast cancer is a significant public health burden. A combination of genetic factors and individual lifestyle habits influences breast cancer risk and tumor behavior. Breast cancer etiology is complex and heterogeneous in its clinical presentation.3

TP53 (tumor protein 53) and XRCC1 (x-ray cross complementing group 1), a tumor suppressor and a DNA repair gene, respectively, contribute to cancer progression. The TP53 gene may cause variation in susceptibility to cancer and give clues about disease progression.4 Furthermore, several genes involved in DNA repair, such as XRCC1, carry genetic polymorphisms that may lead to alterations in DNA repair capacity and affect susceptibility to various cancers, including breast cancer.5-7

Two of the most studied polymorphisms in the TP53 gene are a 16 bp duplication in intron 3 and an arginine to proline substitution in codon 72 in exon 4. This last variation alters the structure of the protein p53,6 resulting in different biochemical and biological properties.9 The Arg72 variant induces apoptosis with about five times more efficiency than the Pro72 variant.6,10,11 However, the Pro72 variant is more efficient at inducing cell cycle arrest in the G1 phase, allowing better repair of damaged DNA.12

XRCC1 is important in the base excision repair process (BER). The gene has two common polymorphisms in codons 194 (Arg194Trp) and 399 (Arg399Gln) that affect the amino acid sequence. Codon 194 is located in the linker region that connects the domains that interact with poly(ADP-ribose) polymerase (PARP) and DNA polymerase β.12 It is related to the binding domains of various proteins including proliferating cell nuclear antigen (PCNA), apurinic/apyrimidinic endonuclease 1 (APE1), and 8-hydroxyguanine DNA-glycosylase (hOGG1). This area is rich in proline, serine, arginine, and lysine residues. Hence, the change from a positively charged Arg to a hydrophobic Trp could affect the binding and efficient repair of DNA.13,14 Codon 399 is located in the C-terminal domain of a breast cancer susceptibility protein 1 (BRCT1) area. Chinese hamster ovary cell lines that carry non-conservative amino acid substitutions in this domain, which binds to PARP, exhibit decreased DNA repair.15

Here we investigate the possible relationship between the genetic background of breast cancer patients, including TP53 and XRCC1 polymorphisms, and tumor clinical pathological features such as tumor grade, estrogen and progesterone receptor status, tumor size, and nodal status.

MATERIALS AND METHODS

We recruited 128 unrelated patients between May 2005 and November 2008 at the Department of Mastology, Fernandes Figueira Institute in Rio de Janeiro (IFF-Fiocruz/Brazil). All patients were diagnosed with infiltrating ductal carcinoma (IDC) and answered questions from a structured questionnaire. Clinicopathological parameters were obtained from hospital clinical records. We used the classification of Scarff-Bloom-Richardson modified by Elston and Ellis as a prognostic parameter and separated the cases in two groups of increasing tumor aggressiveness: low/intermediate with an Elston Grade (EG) of I/II and high with an EG of III. This study was approved by the Ethics Committee of the Fernandes Figueira Institute and all participants signed an informed consent.

Genomic DNA was isolated from peripheral blood (n = 99) and non-tumor breast tissue (n = 29) according to standard procedures.16 TP53 polymorphisms were detected by amplifying genomic DNA with primers previously described.17 XRCC1 polymorphisms were assessed by PCR-RFLP as previously described.18 We were unable to genotype eight samples for TP53 polymorphisms and three for XRCC1 polymorphisms. To ensure the quality of our genotyping results, all genotypes were confirmed by sequencing after PCR during the standardization of the method.

Data analysis was performed using the computer software GraphPad Instat 3.06 for Windows (San Diego California, USA). Fisher’s exact test was used to compare the variables when the number of samples was equal to or less than 5. A p value < 0.05 was defined as significant. The observed numbers for each genotype were compared with those expected for a population in Hardy-Weinberg
Equilibrium by using a goodness of fit Chi-square ($\chi^2$) test applied by the Hardy-Weinberg Equilibrium calculator program.19

RESULTS

To evaluate the association between breast cancer prognosis and the genetic background of breast cancer patients, we decided to carry out a case-control analysis on patients with infiltrating ductal carcinoma (IDC) and with the most studied variant alleles of the TP53 and XRCC1 genes. Table 1 presents the demographical and clinicopathological data for the 128 patients in our study. The principal demographic characteristics of our patients are shown in Table 2 as a function of breast cancer prognosis assessed by Elston Grade classification (EG). None of the analyzed polymorphisms to breast cancer prognosis. The TP53 and XRCC1 polymorphisms in breast cancer patients with EG I/II (low/intermediate aggressiveness) and EG III (high aggressiveness). The allelic frequencies of the TP53 polymorphisms PIN3 Ins16bp and Arg72Pro of 0.2 and 0.4, respectively, and of the XRCC1 polymorphisms Arg194Trp and Arg399Gln of 0.07 and 0.25, respectively, were in accordance with Hardy-Weinberg equilibrium.20-26 Then we proceeded with the association analysis between tumor pathological characteristics and the allelic distribution of the variants (Table 3). We found a statistically positive association with the 194Trp XRCC1 allele and EG III (OR = 4.04; 95% CI = 1.30-12.35; p = 0.018).

Table 1 - Sociodemographic of and tumor characteristics in patients (n = 128).

| Variables                  | n (%)                      |
|----------------------------|----------------------------|
| Age (yr)                   |                            |
| ≤ 30                       | 2 (1.56)                   |
| 31 – 40                    | 22 (17.19)                 |
| 41 – 50                    | 47 (36.72)                 |
| 51 – 60                    | 29 (22.66)                 |
| 61 – 70                    | 17 (13.28)                 |
| > 70                      | 11 (8.59)                  |
| Ethnicity                  |                            |
| White                      | 65 (50.78)                 |
| Non-White                  | 61 (47.66)                 |
| NDa                        | 2 (1.56)                   |
| Menopausal status          |                            |
| Pre-menopausal             | 58 (45.31)                 |
| Post-menopausal            | 64 (50.00)                 |
| NDa                        | 6 (4.69)                   |
| FH breast cancer           |                            |
| Negative                   | 75 (58.59)                 |
| 1° degree*                 | 11 (8.59)                  |
| 2° and/or 3° degrees*      | 27 (21.10)                 |
| NDa                        | 15 (11.72)                 |
| Tumor size                 |                            |
| ≤ 2 cm                     | 57 (44.53)                 |
| > 2 cm a ≤ 5 cm            | 40 (31.25)                 |
| > 5 cm                     | 3 (2.34)                   |
| NDa                        | 28 (21.88)                 |
| Elston Grade               |                            |
| I                          | 28 (21.87)                 |
| II                         | 61 (47.66)                 |
| III                        | 23 (17.97)                 |
| NDa                        | 16 (12.50)                 |
| Lymph node commitment      |                            |
| Negative                   | 45 (35.16)                 |
| Positive                   | 49 (38.28)                 |
| NDa                        | 34 (26.56)                 |
| ER                         |                            |
| Positive                   | 52 (40.63)                 |
| Negative                   | 26 (20.31)                 |
| NDa                        | 50 (39.06)                 |
| PR                         |                            |
| Positive                   | 51 (39.84)                 |
| Negative                   | 28 (21.88)                 |
| NDa                        | 49 (38.28)                 |
| HER2                       |                            |
| Negative                   | 36 (28.12)                 |
| Positive                   | 32 (25.00)                 |
| NDa                        | 60 (46.88)                 |

NDa = no data; ER = estrogen receptor; PR = progesterone receptor; HER2 = human epidermal growth factor receptor type 2; FH = family history; * mother and/or sister.

characteristics, including age, menopausal status, family history, or ethnicity, were differentially distributed between the patients with EG I/II (low/intermediate aggressiveness) and EG III (high aggressiveness). The allelic frequencies of the TP53 polymorphisms PIN3 Ins16bp and Arg72Pro of 0.2 and 0.4, respectively, and of the XRCC1 polymorphisms Arg194Trp and Arg399Gln of 0.07 and 0.25, respectively, were in accordance with Hardy-Weinberg equilibrium.20-26 Then we proceeded with the association analysis between tumor pathological characteristics and the allelic distribution of the variants (Table 3). We found a statistically positive association with the 194Trp XRCC1 allele and EG III (OR = 4.04; 95% CI = 1.30-12.35; p = 0.018).

DISCUSSION

Despite the advances in tumor classification and the development of new therapies, breast cancer evolution remains a mystery. TP53 is a very important tumor suppressor gene and its product, the p53 protein, maintains DNA stability and normal cellular growth. It is at the center of several pathways that lead to cell cycle check points, DNA repair, and apoptosis.27 The TP53 polymorphisms PIN3 Ins16bp and Arg72Pro28-30 and the XRCC1 polymorphism Arg194Trp and Arg399Gln are the most studied variants of each gene.31,32 However, since these studies are based on case-control analysis using different populations and methodologies, the results do not clarify the real load of the polymorphic variants. Here we report the results of a case-case study and determine the contribution of TP53 and XRCC1 polymorphisms to breast cancer prognosis. The histological grading system proposed by Scarff-Bloom-Richardson and modified by Elston and Ellis in 199133 is an important independent prognostic factor for invasive breast tumors. The two groups of patients in our study were rather homogenous in terms of age and ethnicity and our genotyping results for XRCC1 variants Arg194Trp and

Table 2 - Demographics of the subjects by Elston Grade status (n = 112).

| Variables                  | Elston Grade status | p-value |
|----------------------------|---------------------|---------|
| Age (yr)                   | EG III n (%)        | EG I/II n (%) |
| ≤ 30                       | 1 (4.35)            | 2 (2.25)   |
| 31 – 40                    | 1 (4.35)            | 17 (19.10) |
| 41 – 50                    | 6 (26.09)           | 35 (39.32) |
| 51 – 60                    | 9 (39.13)           | 20 (22.47) |
| 61 – 70                    | 3 (13.04)           | 8 (8.99)   |
| > 70                      | 3 (13.04)           | 7 (7.87)   |
| Menopausal status          |                     |         |
| Pre-menopausal             | 6 (26.09)           | 41 (46.07) |
| Post-menopausal            | 14 (60.87)          | 42 (47.19) |
| NDa                        | 3 (13.04)           | 6 (6.74)   |
| FH breast cancer           |                     |         |
| Negative                   | 18 (78.26)          | 50 (56.18) |
| 1° degree*                 | 0                   | 6 (6.74)   |
| 2° and/or 3° degrees*      | 3 (13.04)           | 20 (22.47) |
| NDa                        | 2 (8.70)            | 13 (14.61) |
| Ethnicity                  |                     |         |
| White                      | 12 (52.17)          | 44 (49.44) |
| Non-White                  | 10 (43.48)          | 44 (49.44) |
| NDa                        | 1 (4.35)            | 1 (1.12)   |

EG = Elston Grade; NDa = no data; ER = estrogen receptor; PR = progesterone receptor; FH = family history; * mother and/or sister.
Together these observations indicate that XRCC1 haplotypes Arg194Trp, Arg399Gln may and it is acceptable that some gene XPD found that and Elston XRCC1 TP53 XRCC1, XRCC1 in efficient BER has already been 2.2 Arg/Arg Arg/Pro XRCC1 Arg399Gln and less aggressive 34 with tumor characteristics Overall, no clear indication has rare homozygote); OR = odds ratio; 31 0.018 and any conclusions are very diff 56x170]difficult and complex. and Arg399Gln showed that any conclusions are very 56x180]analysis of 10 studies on breast cancer treated with DNA damaging chemotherapy. be predictive of the outcome of patients with metastatic disease. The role of XRCC1 in efficient BER has already been well determined,6,15,16 and it is acceptable that some gene alterations may change its biological activity and play roles in cancer evolution. A recently published meta-analysis of 37 studies suggests that Arg399Gln is associated with a trend of increased breast cancer risk.31 Another meta-analysis of 10 studies on XRCC1 haplotypes Arg194Trp and Arg399Gln showed that any conclusions are very difficult and complex.32 Overall, no clear indication has been obtained from such studies. Dufflot et al.34 investigated the associations of polymorphisms in the genes XRCC1, XPD, XRCC3, and RAD5 with tumor characteristics in 94 breast cancer patients. While no polymorphisms were well determined,6,15,16 and it is acceptable that some gene alterations may change its biological activity and play roles in cancer evolution. A recently published meta-analysis of 37 studies suggests that Arg399Gln is associated with a trend of increased breast cancer risk.31 Another meta-analysis of 10 studies on XRCC1 haplotypes Arg194Trp and Arg399Gln showed that any conclusions are very difficult and complex.32 Overall, no clear indication has been obtained from such studies. Dufflot et al.34 investigated the associations of polymorphisms in the genes XRCC1, XPD, XRCC3, and RAD5 with tumor characteristics in 94 breast cancer patients. While no polymorphisms were found to be associated with high tumor grade or estrogen receptor negativity, the XRCC1 Arg194Trp variant was not studied. Bewick et al.35 found that XRCC1 Arg399Gln may be predictive of the outcome of patients with metastatic breast cancer treated with DNA damaging chemotherapy. The same was observed in a study of Portuguese patients.36

The authors investigated the possible influence of DNA repair polymorphisms on breast cancer clinicopathological features and described a possible correlation between the Gln/Gln genotype of XRCC1 Arg399Gln and less aggressive tumors, which differs from our observations. Again, the authors did not analyze the Arg194Trp variant. In summary, our study reveals that the XRCC1 Arg194Trp variant is positively associated with breast tumors of Elston grade III, which is a measure of high tumor aggressiveness. However, this initial analysis involves a small sample size, which may contribute to low statistical power. Our findings indicate that further investigations are needed on a larger group to clarify the influence of the Arg194Trp variant in breast cancer development and prognosis.

### REFERENCES

1. Shu XO, Cai Q, Gao YT, Wen W, Jin F, Zheng W. A population-based case-control study of the Arg399Gln polymorphism in DNA repair gene XRCC1 and risk of breast cancer. Cancer Epidemiol Biomarkers Prev. 2003;12:462-7.
2. Ministério da Saúde. Instituto Nacional de Câncer – MS/INCA. (2009). Estimativa 2010 Incidência de câncer no Brasil. Available at: <http://www.inca.gov.br/estimativa/2010/).
3. Kubba AA. Breast cancer and the pill. JRSM. 2003;96:280-3, doi: 10.1258/jrsm.96.6.280.
4. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 2004;119:591-602, doi: 10.1016/j.cell.2004.11.022

### Table 3 - Associations between TP53 and XRCC1 polymorphisms and tumor characteristics

| Variables       | Tumor size (n = 92) | ER (n = 72) | PR (n = 73) | HER2 (n = 63) |
|-----------------|--------------------|-------------|-------------|--------------|
|                 | PIN 3 1.1 1.2 + 2.2 | Arg194Trp  | Arg399Gln   | Arg399Gln    |
| Tumor size      |                    | Arg/Arg     | Arg/Pro + Pro/Pro | Arg/Arg/Gln + Gln/Gln |
| (n = 92)        |                    | Arg/Arg     | Arg/Pro/Trp + Trp/Trp | Arg/Arg/Gln + Gln/Gln |
| ≤ 2 cm          | 34 20              | 51 7        | 0.001       | 0.813        |
| > 2 cm          | 25 13              | 34 6        | 0.765       | 0.539        |
| OR (95% CI)     | 1.00 (ref.) 0.88 (0.37 – 2.11) | 1.00 (ref.) 0.77 (0.32 – 1.82) | 1.00 (ref.) 0.79 (0.33 – 1.66) |
| *p              | 0.828              | 0.660       | 0.765       | 0.539        |
| EG (n = 104)    |                    |             |             |              |
| I / II          | 55 27              | 78 9        | 4.04 (1.30 – 12.35) | 0.018       |
| III             | 12 10              | 15 7        | 0.018       | 0.813        |
| OR (95% CI)     | 1.00 (ref.) 1.70 (0.65 – 4.42) | 1.00 (ref.) 0.91 (0.34 – 2.42) | 1.00 (ref.) 0.85 (0.33 – 2.20) |
| *p              | 0.320              | 1.000       | 0.813       | 0.813        |
| Lymph node      |                    |             |             |              |
| (n = 88)        |                    |             |             |              |
| Negative        | 28 15              | 37 8        | 0.001       | 0.813        |
| Positive        | 28 17              | 42 6        | 0.018       | 0.813        |
| OR (95% CI)     | 1.00 (ref.) 1.13 (0.47 – 2.70) | 1.00 (ref.) 1.07 (0.44 – 2.59) | 1.00 (ref.) 1.79 (0.78 – 4.09) |
| *p              | 0.827              | 1.000       | 0.018       | 0.813        |
| PR (n = 73)     |                    |             |             |              |
| Positive        | 33 15              | 43 8        | 0.001       | 0.813        |
| Negative        | 16 8               | 21 4        | 0.018       | 0.813        |
| OR (95% CI)     | 1.00 (ref.) 1.10 (0.39 – 3.13) | 1.00 (ref.) 1.19 (0.43 – 3.25) | 1.00 (ref.) 1.79 (0.78 – 4.09) |
| *p              | 1.000              | 0.802       | 0.018       | 0.813        |
| HER2 (n = 63)   |                    |             |             |              |
| Negative        | 32 15              | 43 7        | 0.001       | 0.813        |
| Positive        | 18 8               | 22 5        | 0.018       | 0.813        |
| OR (95% CI)     | 1.00 (ref.) 0.95 (0.34 – 2.67) | 1.00 (ref.) 0.85 (0.32 – 2.24) | 1.00 (ref.) 0.59 (0.23 – 1.53) |
| *p              | 1.000              | 0.805       | 0.018       | 0.813        |
| PR (n = 73)     |                    |             |             |              |
| Positive        | 32 15              | 43 7        | 0.001       | 0.813        |
| Negative        | 18 8               | 22 5        | 0.018       | 0.813        |
| OR (95% CI)     | 1.00 (ref.) 0.95 (0.34 – 2.67) | 1.00 (ref.) 0.85 (0.32 – 2.24) | 1.00 (ref.) 0.59 (0.23 – 1.53) |
| *p              | 1.000              | 0.805       | 0.018       | 0.813        |

ER = estrogen receptor; PR = progesterone receptor; *p = Fisher’s exact test (common homozygote x heterozygote + rare homozygote); OR = odds ratio; CI = confidence interval.

Arg399Gln showed the distribution expected in a Brazilian population.23-26 Together these observations indicate that our group of patients is adequate for a case-control study. Our study revealed a statistically significant relationship between the Arg194Trp genotype of XRCC1 and Elston grade III, which indicates a poorly differentiated tumor and, consequently, is related to increased aggressiveness of the disease. The role of XRCC1 in efficient BER has already been well determined,6,15,16 and it is acceptable that some gene alterations may change its biological activity and play roles in cancer evolution. A recently published meta-analysis of 37 studies suggests that Arg399Gln is associated with a trend of increased breast cancer risk.31 Another meta-analysis of 10 studies on XRCC1 haplotypes Arg194Trp and Arg399Gln showed that any conclusions are very
TP53 and XRCC1 polymorphisms in breast cancer

Rodrigues MS et al.

5. Goode EL, Ulrich CM, Potter JD. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev. 2002;11:1513–30.

6. Seedhouse C, Bainton R, Lewis M, Harding A, Russell N, Das-Gupta E. The genotype distribution of the XRCC1 gene indicates a role for base excision repair in the development of therapy-related acute myeloblastic leukemia. Blood. 2002;100:3761–6, doi: 10.1182/blood-2002-04-1152

7. De Ruyc K, Szaszukessel M, De Ruddere I, Dehoorne A, Vral A, Claes K, et al. Polymorphisms in base-excision repair and nucleotide-excision repair genes in relation to lung cancer risk. Mutat Res. 2007;631:101-10, doi:10.1016/j.mrjet.2007.03.010

8. Thomas M, Kalita A, Labrecque S, Pim D, Banks J, Matlashewski G. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol. 1999;19:1092-100.

9. Langerod A, Buckholdt IK, Bregård A, Lönning PE, Andersson TL, Rognum TO, et al. The TP53 codon 72 polymorphism may affect the function of TP53 mutations in breast cancer but not in colorectal carcinomas. Cancer Epidemiol Biomarkers Prev. 2002;11:1684-8.

10. Toyama T, Zhang Z, Nishio M, Hamaguchi M. Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients. Breast Cancer Res. 2007;9:R34, doi:10.1186/bcr1682.

11. Dumont P, Leu JJ, Della Pietra III AC, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nature genetics. 2003;33:357-65, doi:10.1038/ng1093.

12. Øersted DD, Bojersen SE, Tybjaerg-Hansen A, Nordestgaard BG. Tumor suppressor p53 Arg72Pro polymorphism and longevity, cancer survival, and risk of cancer in the general population. JEM. 2007;204:1295-1301, doi:10.1084/jem.20062476.

13. Ladiges WC. Mouse models of XRCC1 DNA repair polymorphisms and the susceptibility to gliomas in individuals from French Canadian descent. BMC Cancer 2008;8:96 doi: 10.1186/1471-2007-8-96.

14. Hu Z, Ma H, Chen F, Wei Q, Shen H. XRCC1 Polymorphisms and cancer risk: A meta-analysis of 38 case-control studies. Cancer Epidemiol Biomarkers Prev. 2005;14:1810-8, doi:10.1158/1055-9965.EPI-04-0793.

15. Shen MR, Jones IM, Mohrenweiser H. Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans. Cancer Res. 1996;56:614-608.

16. Sambrook J, Fritschi EF, Maniatis T. Molecular cloning: a laboratory manual. New York: Cold Spring Harbor Laboratory Press. 1989.

17. Goode EL, Ulrich CM, Potter JD. Polymorphisms in DNA repair genes and associations with cancer risk: A meta-analysis of 38 case-control studies. Cancer Epidemiol Biomarkers Prev. 2002;11:1513–30.

18. Deligezer U, Dalay N. Association of the XRCC1 gene polymorphisms with breast cancer. Carcinogenesis. 2010;31:643–7. Epub 2010 Jan 20, doi: 10.1093/carcin/bgp018.

19. Francisco G, Menezes PR, Eluf-Neto J, Chammas R. Arg72Pro TP53 polymorphism and breast cancer susceptibility: A comprehensive meta-analysis of 302 case-control studies. Int J Cancer. 2010 Sep 30. [Epub ahead of print], doi:10.1002/ijc.25710.

20. Zhang Z, Wang M, Wu D, Wang M, Tong N, Tian Y, et al. P53 codon 72 polymorphism contributes to breast cancer risk: a meta-analysis based on 39 case-control studies. Breast Cancer Res Treat. 2010;120:509-17. doi: 10.1007/s10549-009-0480-4.

21. Hu Z, Li X, Qiu X, He Y, Ring BZ, Song E, et al. Intron 3 16 bp duplication polymorphism of TP53 contributes to cancer susceptibility: a meta-analysis. Carcinogenesis. 2010;31:643-7. Epub 2010 Jan 20, doi: 10.1093/carcin/bgp018.

22. Huang Y, Li L, Yu L. XRCC1 Arg399Gln, Arg194Trp and Arg280His polymorphisms in breast cancer risk: a meta-analysis. Mutagenesis. 2009;24:331-9, doi:10.1093/mutage/gep013.

23. Rossit ARB, Cabral IR, Hackel C, Da Silva RCMA, Fros NDT, Abdel-Rahman SZ. Polymorphisms in the DNA repair gene XRCC1 and susceptibility to alcoholic liver cirrhosis in older Southeastern Brazilians. Cancer Lett. 2002;180:173-82, doi:10.1016/S0304-3835(02)00299-0.

24. Duarte MC, Colombo J, Rossit AR, Caetano A, Borim AA, Worrath D, Silva AE. Polymorphisms of DNA repair genes XRCC1 and XRCC3, interaction with environmental exposure and risk of chronic gastritis and gastric cancer. World J Gastroenterol. 2005;11:693-600.

25. Canalle R, Andrade VSS, Scricelli CA, Queiroz RGP, Tonne LG. Polymorphisms in the thymidylate synthase promoter and the DNA repair genes XRCC1 and XPD in a Brazilian population. Environ Mol Mutagen. 2006;47:725-32, doi:10.1002/em.20269.

26. Faigan-Lotsch P, Rodrigues MS, Esteves V, Vieira R, Amendola LC, Pagnoncelli D, et al. XRCC1 gene polymorphisms in a population sample and in women with a family history of breast cancer from Rio de Janeiro (Brazil). Genet Mol Biol. 2009;32:253-9, doi: 10.1590/S1415-47522009000200008.

27. Olivier M, Holstein M, Hainaut P. TP53 Mutations in Human Cancers: Origins, Consequences, and Clinical Use. Cold Spring Harb Perspect Biol 2010;2:a001008.

28. Francisco G, Menezes PR, Eluf-Neto J, Chammas R, Arg72Pro TP53 polymorphism and breast cancer susceptibility: A comprehensive meta-analysis of 302 case-control studies. Int J Cancer. 2010 Sep 30. [Epub ahead of print], doi:10.1002/ijc.25710.

29. Zhang Z, Wang M, Wu D, Wang M, Tong N, Tian Y, et al. P53 codon 72 polymorphism contributes to breast cancer risk: a meta-analysis based on 39 case-control studies. Breast Cancer Res Treat. 2010;120:509-17. doi: 10.1007/s10549-009-0480-4.

30. Hu Z, Li X, Qiu X, He Y, Ring BZ, Song E, et al. Intron 3 16 bp duplication polymorphism of TP53 contributes to cancer susceptibility: a meta-analysis. Carcinogenesis. 2010;31:643-7. Epub 2010 Jan 20, doi: 10.1093/carcin/bgp018.

31. Huang Y, Li L, Yu L. XRCC1 Arg399Gln, Arg194Trp and Arg280His polymorphisms in breast cancer risk: a meta-analysis. Mutagenesis. 2009;24:331-9, doi:10.1093/mutage/gep013.

32. Saadat M. Haplotype analysis of XRCC1 (at codons 194 and 399) and XRCC3 (at codons 280 and 399) in breast cancer patients. Breast Cancer Res Treat. 2010;124:785-91. Epub 2010 Apr 17, doi: 10.1007/s10549-010-0895-y.

33. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19:403-10, doi:10.1111/j.1365-2559.1991.tb02299.x.

34. Dufloth RM, Arruda A, Heinrich JKR, Schmitt F, Zeferino LC. The investigation of DNA repair polymorphisms with histopathological characteristics and hormone receptors in a group of Brazilian women with breast cancer. Genet Mol Res. 2008;7:574-82, doi:10.4238/vol7-3grm376.

35. Bewick MA, Conlon MSC, Lafrenie RM. Polymorphisms in XRCC1, XRCC3, and CCND1 and Survival After Treatment for Metastatic Breast Cancer. J Clin Oncol. 2006;24:5645-51, doi: 10.1200/JCO.2006.05.9923.

36. Costa S, Pinto D, Pereira D, Rodrigues H, Cameselle-Teijeiro J, Medeiros R, et al. XRCC1 Arg399Gln and RAD51 50UTR G135C polymorphisms and their outcome in tumor aggressiveness and survival of Portuguese breast cancer patients. Breast Cancer Res Treat. 2008;109:183-5, doi: 10.1007/s10549-007-9637-1.